Anika Therapeutics, Inc. provided earnings guidance for the fiscal year 2024. The company expects revenue for fiscal year 2024 of $168 million to $173 million, representing growth of 1% to 4% compared to 2023.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.82 USD | +2.24% | -7.19% | +13.00% |
May. 08 | Earnings Flash (ANIK) ANIKA THERAPEUTICS Reports Q1 EPS $0.09 | MT |
May. 08 | Earnings Flash (ANIK) ANIKA THERAPEUTICS Reports Q1 Revenue $40.5M, vs. Street Est of $39.1M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.00% | 370M | |
-2.61% | 88.47B | |
+3.55% | 40.71B | |
-13.93% | 32.43B | |
+55.45% | 24.28B | |
-15.47% | 15.52B | |
-41.29% | 12.17B | |
-14.92% | 12.01B | |
-11.75% | 12B | |
+7.57% | 8.87B |
- Stock Market
- Equities
- ANIK Stock
- News Anika Therapeutics, Inc.
- Anika Therapeutics, Inc. Provides Earnings Guidance for the Fiscal Year 2024